Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

1. World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians

World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new account Email Can't sign in? Forgot your password? Enter your email address below and we will send you the reset instructions Email (...) States, the incidence of hepatitis C virus (HCV) infection is 1.2 per 100 000 persons, the prevalence is 2.4 million cases, and annual mortality is more than 15 000 deaths ( , ). Eliminating hepatitis will require diagnosis of 90% of those infected followed by treatment of 80% of those diagnosed ( ). The World Health Organization (WHO) updated its evidence-based guideline on chronic HCV infection in July 2018 ( ) ( ). Although the WHO guideline is primarily targeted toward policymakers in low

2020 American College of Physicians

2. Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C

Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C '); } else { document.write(' '); } ACE | Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C Search > > Direct-acting antiviral agent for treating genotype 2 to 6 chronic hepatitis C - Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C First published on 2 January 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Sofosbuvir 400 mg (...) /velpatasvir 100 mg tablet for treating genotype 2, 3, 4, 5, or 6 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults; and Glecaprevir 100 mg/pibrentasvir 40 mg tablet for treating genotype 2, 3, 4, 5, or 6 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (with or without sofosbuvir)-experienced, or sofosbuvir plus ribavirin

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

3. Direct-acting antiviral agents for genotype 1 chronic hepatitis C

Direct-acting antiviral agents for genotype 1 chronic hepatitis C '); } else { document.write(' '); } ACE | Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C Search > > Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C - Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C First published on 1 October 2018 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Sofosbuvir 400 mg (...) /velpatasvir 100 mg tablet for treating genotype 1 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced, or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults. Glecaprevir 100 mg/pibrentasvir 40 mg tablet for treating genotype 1 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (with or without sofosbuvir)-experienced, or sofosbuvir plus ribavirin-experienced adults. Sofosbuvir

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

4. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper

Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper Downloaded from https://journals.lww.com/jpgn by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3IJrtBKuSsQVsKRVaZGM1l4DvatJ7+0OA9ytY7fNKvII= on 09/01/2020 Downloaded from https://journals.lww.com/jpgn by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3IJrtBKuSsQVsKRVaZGM1l4DvatJ7+0OA9ytY7fNKvII= on 09/01/2020 Copyright © ESPGHAN and NASPGHAN (...) . All rights reserved. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper Daniel H. Leung, y James E. Squires, z Ravi Jhaveri, § Nanda Kerkar, jj Chuan-Hao Lin, Parvathi Mohan, # Karen F. Murray, Regino P. Gonzalez-Peralta, yy Eve A. Roberts, and zz Shikha S. Sundaram ABSTRACT In 1989, a collaboration between the Centers for Disease Control (CDC) and a California biotechnology company identi?ed the hepatitis C virus (HCV

2020 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

5. Hepatitis C Virus. (Abstract)

Hepatitis C Virus. Hepatitis C virus (HCV) is the most common bloodborne pathogen in the United States, chronically affecting approximately 2.4 million Americans, most of whom are unaware of the infection. Highly effective, well-tolerated therapies are now available with markedly simplified treatment algorithms. Eradication of HCV is a national goal. Increased efforts to extend access to treatment to populations that traditionally are difficult to treat, such as persons who inject drugs

2020 Annals of Internal Medicine

6. Hepatitis B virus persistence and reactivation. (Full text)

Hepatitis B virus persistence and reactivation. Hepatitis B virus (HBV) infection causes chronic hepatitis and has long term complications. Individuals ever infected with HBV are at risk of viral reactivation under certain circumstances. This review summarizes studies on HBV persistence and reactivation with a focus on the definitions and mechanisms. Emphasis is placed on the interplay between HBV replication and host immunity as this interplay determines the patterns of persistence following

2020 BMJ PubMed abstract

7. Bulevirtide (Hepcludex) - chronic (long-term) hepatitis delta virus (HDV)

Bulevirtide (Hepcludex) - chronic (long-term) hepatitis delta virus (HDV) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/312782/2020 EMEA/H/C/004854 Hepcludex (bulevirtide (...) ) An overview of Hepcludex and why it is authorised in the EU What is Hepcludex and what is it used for? Hepcludex is an antiviral medicine used to treat chronic (long-term) hepatitis delta virus (HDV) infection in adults with compensated liver disease (when the liver is damaged but is still able to work), when the presence of viral RNA (genetic material) has been confirmed by blood tests. HDV is an 'incomplete' virus, because it cannot replicate in cells without the help of another virus, the hepatitis B

2020 European Medicines Agency - EPARs

8. Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy

Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update | Journal of Clinical Oncology Search in: Menu > > > > Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01757 Journal of Clinical Oncology - published online before print July 27, 2020 PMID (...) : Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update , MD, MPH 1 x Jessica P. Hwang ; , MD, MPH 2 x Jordan J. Feld ; , MD 3 x Sarah P. Hammond ; , MD, MPH 4 x Su H. Wang ; , MD, MMM 5 x Devena E. Alston-Johnson ; , JD 6 x Donna R. Cryer ; , MD 7 x Dawn L. Hershman ; , MD, MPH 8 x Andrew P. Loehrer ; , MD 9 x Anita L. Sabichi ; , MD, MACP 10 x Banu E. Symington ; , MD, MPH 11 x Norah Terrault ; , MD, MAS 12 x Melisa L. Wong ; , PhD

2020 American Society of Clinical Oncology Guidelines

9. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement (Full text)

Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement - The Journal of Heart and Lung Transplantation Go search , P418-432, May 01, 2020 Powered By Mendeley Share on Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement Saima (...) Jeffrey Teuteberg,MD Maria Crespo,MD Haifa Lyster,PharmD Laura Lourenco,PharmD Sara Machado,MD Michael Shullo,Pharm D Matthew Hartwig,MD Miranda Peraskeva,MD Cameron Wolfe,MD Kiran Khush,MD Michael Ison,MD Shelley Hall,MD Joshua Mooney,MD Steve Ivulich,PharmD Marcelo Cypel,MD Victor Pretorius,MBBS Patricia Uber,PharmD Evan Kransdorf,MD, PhD Adam Cochrane,PharmD, MPH Alan Glanville,MD Jennifer Gray,PharmD Published: March 18, 2020 DOI: The advent of therapies for successful treatment of hepatitis C

2020 International Society for Heart and Lung Transplantation PubMed abstract

10. USPSTF recommends screening adults 18 to 79 years for hepatitis C virus infection (moderate certainty). (Abstract)

USPSTF recommends screening adults 18 to 79 years for hepatitis C virus infection (moderate certainty). Owens DK, Davidson KW, Krist AH, et al. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323:970-5. 32119076.

2020 Annals of Internal Medicine

11. Hepatitis C Virus Infection in Adolescents and Adults: Screening

Hepatitis C Virus Infection in Adolescents and Adults: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Adults aged 18 to 79 years The USPSTF recommends screening for hepatitis C virus (HCV) infection in adults aged 18 to 79 years. B View the Clinical Summary in What does the USPSTF recommend? For adults aged 18 to 79 years: Grade B Screen adults for hepatitis C virus (HCV) infection. To whom does (...) evidence to determine how often to screen persons at increased risk. What are other relevant USPSTF recommendations? The USPSTF has made recommendations on screening for hepatitis B virus infection in pregnant persons, hepatitis B virus infection in adults, and HIV infection. These recommendations are available at . Where to read the full recommendation statement? Visit the USPSTF website to read the full recommendation statement. This includes more details on the rationale of the recommendation

2020 U.S. Preventive Services Task Force

12. Hepatitis E: symptoms, transmission, prevention, treatment

Hepatitis E: symptoms, transmission, prevention, treatment Hepatitis E: symptoms, transmission, prevention, treatment - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis E: symptoms, transmission, prevention, treatment The symptoms, means of transmission, best means of prevention and treatment of hepatitis E. Published 1 June 2014 Last updated 16 July 2019 — From: Documents HTML Details (...) This document explains hepatitis E, describing the: symptoms means of transmission best means of prevention and treatment Published 1 June 2014 Last updated 16 July 2019 16 July 2019 Added provisional data for January to March 2019. 8 March 2019 Updated the number of hepatitis E cases in 2017 and 2018. 7 November 2018 Added provisional data for January to September 2018. 10 August 2018 Added provisional data for January to June 2018. 1 August 2018 Updated 2017 figures. 1 February 2018 Updated number

2020 Public Health England

13. Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis. (Abstract)

Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis. Previous study has shown a positive relationship between the hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and cholangiocarcinoma (CCA); however, their correlation with different anatomical sites of CCA (i.e. ICC and ECC) has not been revealed. This study aims to evaluate the association of HBV or HCV infection with CCA

2020 The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

14. Magnitude of and Prediction for Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Taking Entecavir or Tenofovir Therapy: A Systematic Review. (Abstract)

Magnitude of and Prediction for Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Taking Entecavir or Tenofovir Therapy: A Systematic Review. Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have been shown to reduce incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This systematic review aims to evaluate the magnitude, change over time, and prediction of residual HCC risks in CHB patients treated with ETV/TDF therapy.Available (...) , cirrhosis (fibrosis grade) and hepatic function. Conflicting results were reported in 7 individual studies and 2 meta-analyses that compared ETV vs. TDF.The residual risk of HCC remains during ETV/TDF treatment in CHB patients with cirrhosis, but declines over time. Risk stratification is attainable by validated predictive scores.This article is protected by copyright. All rights reserved.

2020 Journal of gastroenterology and hepatology

15. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. (Full text)

The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. There are uncertainties about the epidemic patterns of hepatitis delta virus (HDV) infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among hepatitis B surface antigen (HBsAg)-positive people.We searched Pubmed, EMBASE and Scopus for studies (...) , and those with hepatitis C virus or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10, 26) for cirrhosis and 20% (8, 33) for HCC.An estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precisions of burden estimates.Copyright © 2020. Published by Elsevier B.V.

2020 Journal of Hepatology PubMed abstract

16. Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients. (Abstract)

Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients. The prevalence of co-infection of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) is high and increases risk of hepatitis B chronicity and mortality. Despite guidelines for HIV-infected patients to be immunized against HBV, the immunogenicity of the HBV vaccination in HIV-infected patients is lower than that in the HIV-seronegative population.In this study (...) , we performed a systematic review of the literature and meta-analysis of randomized clinical trials to investigate the response rate to an increased dose of HBV vaccination in HIV-infected patients. A fixed-effects model, with heterogeneity and sensitivity analyses, was used. We identified nine studies involving 970 HIV-positive vaccine recipients.The study results were divided into two groups, depending on the time when antibody against hepatitis surface antigen was measured. Results showed

2020 Vaccine

17. Seroprevalence of hepatitis E virus infection in pregnant women: a systematic review and meta-analysis. (Full text)

Seroprevalence of hepatitis E virus infection in pregnant women: a systematic review and meta-analysis. Hepatitis E virus (HEV) infection has emerged as a global public health problem that affects millions of people every year.Systematically review data on the prevalence of HEV IgG antibody among pregnant women around the world.Potentially relevant studies were identified by a search of PubMed and ScienceDirect, and by a manual search of the reference lists of identified studies.Observational

2020 Annals of Saudi Medicine PubMed abstract

18. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. (Full text)

Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Studies have shown that nucleos(t)ide analogue (NA) treatment can reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but it is unclear which NA is most effective. We performed a meta-analysis and systematic review comparing the efficacies of NAs in CHB patients.We searched literature databases for randomized controlled trials (...) (RCTs) and observational studies that analyzed the hepatic biochemical response, virological response, seroconversion rate, drug resistance rate, and HCC incidence rate in CHB patients treated with NAs. Meta-analyses were performed with RevMan and Stata/SE software.Twelve cohort studies and one RCT were selected, in which entecavir (ETV), lamivudine (LAM), telbivudine (LdT), and/or tenofovir disoproxil fumarate (TDF) were evaluated in CHB patients. The meta-analysis showed that ETV was superior

2020 Gut and liver PubMed abstract

19. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. (Full text)

The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. Hepatitis E virus (HEV), as an emerging zoonotic pathogen, is a leading cause of acute viral hepatitis worldwide, with a high risk of developing chronic infection in immunocompromised patients. However, the global epidemiology of HEV infection has not been comprehensively assessed. This study aims to map the global prevalence and identify the risk factors of HEV infection by performing a systematic

2020 Liver international : official journal of the International Association for the Study of the Liver PubMed abstract

20. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. (Abstract)

Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Objectives: Chronic hepatitis B (CHB) is a major global health problem caused by hepatitis B virus (HBV) infection, and can put patients at high risk of death from cirrhosis and liver cancer. However, CHB can be treated with nucleos(t)ide analogues. We aimed to evaluate the effectiveness and safety of nucleos(t)ide analogues for the treatment of CHB patients.Methods: A systematic

2020 Expert review of anti-infective therapy